Our study also demonstrated an overall trend toward improvement in analyses of time to symptom resolution ( Table 2 and Supplementary Table 5 ); however, regardless of the statistical methods used, all differences were less than 24 hours in magnitude.
← all excerpts
Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial.
1
—
—